Literature DB >> 3994147

Effects of vasodilators on canine cardiopulmonary function when a decrease in cardiac output complicates an increase in right ventricular afterload.

M Ghignone, L Girling, R M Prewitt.   

Abstract

In canine oleic acid pulmonary edema, we investigated acute cardiopulmonary effects of nitroprusside (NP) before (NP1), and after (NP2) pulmonary vascular resistance (PVR) was increased via glass bead embolization. In the setting of increased PVR and reduced cardiac output (CO), acute cardiopulmonary effects of NP and hydralazine were compared. Oleic acid increased (p less than 0.05) pulmonary shunt (Qs/Qt) from 15 to 24%, but did not alter PVR. Cardiac output decreased (p less than 0.01) 31% with oleic acid from 4.2 to 2.9 1 X min-1 and systemic vascular resistance (SVR) increased (p less than 0.01). When PVR was normal, NP reduced (p less than 0.05) blood pressure (BP) from 148 to 123 mmHg, decreased SVR 31%, and increased (p less than 0.05) CO and Qs/Qt. Glass bead embolization increased (p less than 0.001) PVR from 2.2 to 20 mgHg X 1-1 X min and reduced (p less than 0.01) CO 23%, from 2.6 to 2 L/min. The Qs/Qt did not increase with embolization. In contrast to effects of NP1, when RV afterload was increased, CO fell (p less than 0.05) with NP2 from 2 to 1.6 1 X min-1. Alternatively, hydralazine improved cardiopulmonary function. In the setting of increased RV afterload, SVR and PVR decreased (p less than 0.01) 48 and 29%, respectively, with hydralazine. Corresponding to the decrease in resistance, CO increased (p less than 0.001) 84% with hydralazine, from 1.9 to 3.5 1 X min-1. Also, BP and Qs/Qt remained constant and arterial O2 tension increased (p less than 0.05) with hydralazine, from 113 to 152 mmHg.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994147     DOI: 10.1164/arrd.1985.131.4.527

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  3 in total

Review 1.  The pulmonary circulation in acute lung injury: a review of some recent advances.

Authors:  M Leeman
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

2.  Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

Authors:  R Demnati; M C Michoud; A Jeanneret-Grosjean; H Ong; P Du Souich
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

3.  Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans.

Authors:  Natalie E Taylor; Sarah E Baker; Thomas P Olson; Sophie Lalande; Bruce D Johnson; Eric M Snyder
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.